As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
Below, we look at several companies that investors willing to take a bit of a risk on the pharma industry may want to keep watch over. Two have key upcoming FDA decisions looming, although on slightly different timelines. The third offers a varied approach: as a company with multiple products already on the market, it doesn't rely quite so heavily on a single strong data release or FDA announcement, though it can still benefit from such developments.
